GlassScriptPhysician profile
Harry H Lin
NPI 1538105895
$2,538.58
in general payments reported to CMS, 2019-2025
24 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $195 · 2021: $300 · 2022: $360 · 2023: $535 · 2024: $714 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.06 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $332.18 | 2019-2025 | |
| Novo Nordisk INC | $304.59 | 2022-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $237.99 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $234.70 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $157.44 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $155.78 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $138.84 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $137.54 | 2019-2021 | |
| Glaxosmithkline, LLC. | $129.87 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $117.85 | 2023-2024 | Quviviq |
| Incyte Corporation | $90.71 | 2023-2024 | Opzelura |
| Pfizer INC. | $81.29 | 2024-2025 | |
| Abbvie INC. | $66.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.61 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $54.41 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $44.80 | 2024-2025 | Zoryve |
| Abbott Laboratories | $42.73 | 2022 | |
| Renalytix Ai, INC. | $34.92 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Seqirus USA INC | $27.52 | 2019 | |
| Shield Therapeutics INC | $24.84 | 2022 | |
| Merck Sharp & Dohme LLC | $18.83 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $14.60 | 2021 | |
| Almatica Pharma LLC | $14.46 | 2023 | Loreev Xr |
| Redhill Biopharma INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.